co-amilozide co-amilozide co-amilozide (ban) is a non-proprietary combination of amiloride and hydrochlorothiazide. co-amilozide is used in the treatment of hypertension and congestive heart failure with the tendency of the thiazide to cause low potassium levels (hypokalaemia) offset by the potassium-sparing effects of amiloride. co-amilozidecombination ofamiloridepotassium-sparing diuretichydrochlorothiazidethiazide diureticclinical dataahfs/drugs.cominternational drug namesroutes ofadministrationoralatc codec03ea01 (who) legal statuslegal status uk: pom (prescription only) identifierscas number57017-78-4pubchem cid107748chemspider96911 ycomptox dashboard (epa)dtxsid90218652 (verify) formulation two strengths of co-amilozide are currently available in the uk: 2.5 mg amiloride and 25 mg hydrochlorothiazide, ban of co-amilozide 2.5/25 (brand name moduret 25) 5 mg amiloride and 50 mg hydrochlorothiazide, ban of co-amilozide 5/50 (brand name moduretic) in north america: moduretic (u.s., canada) moduretic 5-50 (u.s., canada) novamilor (canada) side effects the most common side effect is headache (about 8% of people taking it) and nausea, loss of appetite, weakness, rash and dizziness (each about 3%). common side effects (1/10 - 1/100) include: general: weakness, fatigue, loss of appetite, headache, dizziness. circulatory system: arrhythmia. gastrointestinal: nausea, diarrhea, abdominal pain. skin: exanthema, itching. respiratory system: shortness of breath, cough. metabolic: elevated blood sugar in diabetic patients, elevated uric acid levels in the blood. musculoskeletal: pain in the limbs.